Table 1 Baseline demographics and disease characteristics.
From: Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
Epacadostat 100 mg (n = 62) | Epacadostat 300 mg (n = 8) | Total (N = 70) | |
|---|---|---|---|
Male, n (%) | 43 (69.4) | 4 (50.0) | 47 (67.1) |
Mean age, years (SD) | 57.0 (11.92) | 53.0 (11.31) | 56.5 (11.84) |
Age ≥65 years, n (%) | 17 (27.4) | 2 (25.0) | 19 (27.1) |
Race, n (%) | |||
White | 56 (90.3) | 5 (62.5) | 61 (87.1) |
Black/African American | 3 (4.8) | 0 | 3 (4.3) |
Asian | 2 (3.2) | 0 | 2 (2.9) |
Other | 1 (1.6) | 3 (37.5) | 4 (5.7) |
Solid tumor type, n (%) | |||
Colorectal | 30 (48.4) | 3 (37.5) | 33 (47.1) |
Gastric | 1 (1.6) | 0 | 1 (1.4) |
HNSCC | 8 (12.9) | 0 | 8 (11.4) |
Melanoma | 13 (21.0) | 0 | 13 (18.6) |
NSCLC | 6 (9.7) | 0 | 6 (8.6) |
Urothelial | 4 (6.5) | 0 | 4 (5.7) |
Other | 0 | 5 (62.5) | 5 (7.1) |
Disease status, n (%) | |||
Advanced | 1 (1.6) | 1 (12.5) | 2 (2.9) |
Metastatic | 61 (98.4) | 7 (87.5) | 68 (97.1) |
Prior lines of therapy, n (%) | |||
0 | 1 (1.6) | 1 (12.5) | 2 (2.9) |
1 | 15 (24.2) | 4 (50.0) | 19 (27.1) |
2 | 14 (22.6) | 2 (25.0) | 16 (22.9) |
≥3 | 32 (51.6) | 1 (12.5) | 33 (47.1) |
Prior treatment, n (%) | |||
Systemic therapy | 62 (100.0) | 8 (100.0) | 70 (100.0) |
Radiotherapy | 28 (45.2) | 4 (50.0) | 32 (45.7) |
Surgery | 50 (80.6) | 5 (62.5) | 55 (78.6) |
PD-1 and PD-L1–targeted therapy | 32 (51.6) | 2 (25.0) | 34 (48.6) |
